{"id":"etoricoxib-tizanidine-fixed-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This fixed-dose combination targets pain and muscle spasticity through dual mechanisms: etoricoxib blocks cyclooxygenase-2 (COX-2), reducing prostaglandin-mediated inflammation and pain signaling, while tizanidine activates alpha-2 adrenergic receptors in the spinal cord and brainstem to suppress motor neuron activity and reduce muscle tone. Together, they provide complementary analgesic and muscle-relaxant effects for musculoskeletal conditions.","oneSentence":"Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while tizanidine acts as a central alpha-2 adrenergic agonist to relieve muscle tension.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:54.108Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute musculoskeletal pain with muscle spasm"},{"name":"Chronic pain conditions with associated muscle tension"}]},"trialDetails":[{"nctId":"NCT06863662","phase":"PHASE3","title":"Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2024-09-18","conditions":"Acute Low-back Pain, Muscle Spasm; Back Pain","enrollment":136},{"nctId":"NCT01979510","phase":"PHASE3","title":"Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11","conditions":"Low Back Pain","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Etori + Tiza"],"phase":"phase_3","status":"active","brandName":"Etoricoxib + Tizanidine fixed dose","genericName":"Etoricoxib + Tizanidine fixed dose","companyName":"Laboratorios Silanes S.A. de C.V.","companyId":"laboratorios-silanes-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while tizanidine acts as a central alpha-2 adrenergic agonist to relieve muscle tension. Used for Acute musculoskeletal pain with muscle spasm, Chronic pain conditions with associated muscle tension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}